Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO versus METADATE CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO versus METADATE CD.
EVEKEO vs METADATE CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2%
Category C
Category C
CNS Stimulant
CNS Stimulant